H.C. Wainwright analyst Ed Arce maintained a Buy rating on Arcturus Therapeutics (NASDAQ:ARCT) on Friday, setting a price target of $78, which is approximately 51.10% above the present share price of $51.62.
Arce expects Arcturus Therapeutics to post earnings per share (EPS) of -$0.55 for the fourth quarter of 2020.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Arcturus Therapeutics, with an average price target of $75.8.
The analysts price targets range from a high of $82 to a low of $65.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $2.32 million and a net profit of -$10.04 million. The company's market cap is $1.26 billion.
According to TipRanks.com, H.C. Wainwright analyst Ed Arce is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 14.2% and a 41.98% success rate.
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.